Skip to main content

CNS Tumor clinical trials at UCSF
2 research studies open to new patients

  • Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions

    open to eligible people ages 2-22

    This is a 5-part, open-label, Phase 1/1b multicenter, dose escalation study in pediatric patients with relapsed refractory solid tumors; 2) primary CNS tumors; 3) neuroblastoma; 4) non-neuroblastoma, extracranial solid tumors with NTRK1/2/3, ROS1 or ALK gene rearrangements; and 5) patients who are otherwise eligible but unable to swallow capsules. The study is designed to explore the safety, maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D), pharmacokinetics, and antitumor activity of entrectinib.

    San Francisco, California and other locations

  • Vigilant ObservatIon of GlIadeL WAfer ImplaNT Registry

    open to eligible people ages 18 years and up

    This is a prospective, observational registry in patients who have been prescribed Gliadel Wafer by the physician as part of usual care.

    San Francisco, California and other locations

Last updated: